Veradermics Incorporated (MANE)
NYSE: MANEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MANE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.04B
- EPS (TTM)
- -$3.89
- Dividend yield
- None
- 52-week range
- 32.00 – 156.63
- Day range
- 118.99 – 123.70
- Volume / Avg
- 374.92K / 738.22K
- Beta
- —
- Shares outstanding
- 42.20M
52-week range
MANE stock today
Veradermics (MANE) closed at $119.52 on Nov 20, down 3.92% (-$4.87), versus the S&P 500's 3.70% decline. Shares are 23.7% below their 52-week high of $156.63, set on Nov 11, 2026 and 273.5% above the 52-week low of $32.00, in the middle of the past year's range. Veradermics has posted a net loss over the last twelve months (EPS of -$3.89), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Veradermics
Company profileVeradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Reid Waldman M.D.
- Headquarters
- New Haven, CT
- Employees
- 51
- IPO year
- 2026
- Website
- veradermics.com
Financial highlights
Full financialsVeradermics reported a net loss of $70.0 million, compared with a loss of $26.5 million a year earlier. Diluted earnings per share came in at -$111.91.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $-70.00M | $-26.49M |
| EPS (diluted) | $-111.91 | $-37.05 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$187.33+56.74%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.50 vs $-0.59
- Surprise
- +15.25%
MANE news
All MANE news- Veradermics reports Q3 resultsSeeking Alpha
- Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressBusiness Wire
- Why is Veradermics stock climbing today?Investing.com
- Veradermics stock rises on 12-month hair growth trial dataInvesting.com
- Why This Hair Restoration Biotech's Shares Are SoaringNasdaq
- Veradermics stock surges as hair loss drug meets Phase 3 goalsInvesting.com
- Veradermics scores another late-stage trial win for hair loss therapySeeking Alpha
- Veradermics To Review Phase 3 Study 304 Results For VDPHL01 In Male Pattern Hair Loss; Stock UpNasdaqMANE, DDS
Veradermics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BLTEBelite Bio Inc ADR | 127.38 | -15.65% | $5.17B | vs MANE |
| LQDALiquidia Corporation | 54.43 | -3.88% | $4.90B | vs MANE |
| ERASErasca Inc. | 13.61 | -4.29% | $4.78B | vs MANE |
| DNTHDianthus Therapeutics Inc. | 84.55 | -0.33% | $4.76B | vs MANE |
| PTCTPTC Therapeutics Inc. | 56.42 | -3.27% | $4.71B | vs MANE |
| COGTCogent Biosciences Inc. | 26.72 | -3.69% | $4.65B | vs MANE |
| GRFSGrifols S.A. ADR | 8.15 | -0.61% | $5.55B | vs MANE |
| TVTXTravere Therapeutics Inc. | 47.00 | -2.69% | $4.51B | vs MANE |
Indexes, lists and sector
Veradermics stock FAQ
What is Veradermics's stock price today?
MANE last traded at $119.52 as of Nov 20, 4:00 PM EST, down 3.92% on the day. Prices are delayed at least 15 minutes.
Who is Veradermics's CEO?
Dr. Reid Waldman M.D. is the chief executive officer of Veradermics Incorporated, which has about 51 employees.
What is the MANE 52-week high?
The 52-week high for MANE is $156.63 and the 52-week low is $32.00. The stock is currently 23.7% below its high.